Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported an open-market sale of common stock. On February 26, 2026, Hunt sold 2,693 shares at a weighted average price of $661.5413 per share in open-market transactions. After the sale, Hunt directly owned 19,898.944 common shares and indirectly owned 160 shares jointly with a spouse. A footnote explains that the sale prices ranged from $661.35 to $661.8275 per share, with detailed trade breakdowns available upon request.
IDEXX Laboratories, Inc. files its Annual Report describing a diversified diagnostics business focused on companion animal health, water quality, and livestock, poultry and dairy testing, plus a smaller human point-of-care line. The company highlights extensive use of AI across analyzers, imaging and software, and a cloud ecosystem that connects in-clinic instruments with reference labs and telemedicine.
IDEXX reports $251.2 million of 2025 research and development expense, or 5.8% of consolidated revenue, up from $219.8 million (5.6%) in 2024 and $191.0 million (5.2%) in 2023. It notes significant regulatory oversight globally, reliance on some sole‑source suppliers, increasing PFAS and AI regulation, and strong human‑capital programs supporting about 11,000 employees in 34 countries.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.
On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.
IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.
On the same date, she executed open-market sales of 945 and 519 common shares at weighted average prices of $628.646 and $628.56 per share, respectively. After these transactions, she held 648 IDEXX common shares directly and 8,173 shares indirectly through the Sophie V. Vandebroek Revocable Trust.
IDEXX Laboratories executive Sharon E. Underberg reported multiple equity award activities. On February 12, 2026, she received grants of 3,738 non-qualified stock options, 162 incentive stock options, and 891 restricted stock units (RSUs), with the options and RSUs vesting in scheduled installments beginning February 14, 2027 and one option grant vesting on February 14, 2030.
On February 14, 2026, several prior RSU awards vested, converting into a total of 832 shares of common stock. To cover tax obligations, 251 shares of common stock were withheld at a price of $629.35 per share. After these transactions, she directly owned 6,940.654 shares of IDEXX common stock.
Smith Martin Alexander reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,715 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 188 shares.
IDEXX Laboratories Executive Vice President Michael Schreck reported a series of equity compensation transactions. On February 12, 2026, he was granted 4,625 non-qualified stock options and 162 incentive stock options, along with 1,094 and 1,620 restricted stock units (RSUs), all at a stated price of 0.0000 per share. Footnotes state these options become exercisable in installments beginning February 14, 2027 and on February 14, 2030, while the RSUs vest over three or four annual installments starting February 14, 2027 and February 14, 2026.
On February 14, 2026, multiple RSU awards vested and were converted into an aggregate of 1,959 shares of common stock at a stated price of 0.0000 per share. In a separate transaction coded “F,” 876 common shares at 629.35 per share were disposed of to satisfy tax withholding, leaving 3,088.709 common shares owned directly.
MAZELSKY JONATHAN JAY reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 18,436 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,099 shares.